Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on the stock and has a $135.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn has given his Buy rating due to a combination of factors related to Gilead Sciences’ strategic positioning and robust pipeline. Despite a recent clinical hold on trials for certain HIV treatments, Flynn believes this setback has a limited impact on the company’s near to medium-term prospects. The hold affects only specific early-stage trials and does not extend to the broader HIV treatment pipeline.
Flynn emphasizes the strength of Gilead’s existing portfolio, particularly the potential of Lenacapavir, which has shown no adverse effects in extensive studies. The company’s commitment to resolving the clinical hold issues and its ongoing efforts to expand its treatment options further support the Buy rating. Gilead’s proactive approach in working with regulatory bodies and its focus on innovation in HIV treatment underpin Flynn’s positive outlook.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $126.00 price target.
GILD’s price has also changed moderately for the past six months – from $92.340 to $110.090, which is a 19.22% increase.